Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03356483 · ClinicalTrials.gov registry record · Phase 1
Efficacy of Psilocybin in OCD: a Double-Blind, Placebo-Controlled Study.
A Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT03356483 is a Phase 1 study that has completed, run by Yale University. The registered enrollment target is 31 participants.
The verdict
NCT03356483, a Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
This study aims to investigate the effects of oral psilocybin on OCD symptomatology and provide the first evidence of the neural mechanism that may mediate psilocybin's purported therapeutic effects on OCD.
Interventions
- DRUG Psilocybin (0.25mg/kg)
- DRUG Niacin (250mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2018-11-13 |
| Est. Completion | 2024-07-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03356483
The ClinicalTrials.gov registry entry for NCT03356483 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Psilocybin (0.25mg/kg) is the first listed.
NCT03356483 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03356483 about?
NCT03356483 is a clinical study titled "Efficacy of Psilocybin in OCD: a Double-Blind, Placebo-Controlled Study.". This study aims to investigate the effects of oral psilocybin on OCD symptomatology and provide the first evidence of the neural mechanism that may mediate psilocybin's purported therapeutic effects on OCD.
What is the current status of trial NCT03356483?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2018-11-13. Estimated completion is 2024-07-25.
What interventions are being tested in trial NCT03356483?
The interventions under investigation include: Psilocybin (0.25mg/kg) (DRUG), Niacin (250mg) (DRUG).
Who is sponsoring clinical trial NCT03356483?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.